Cargando…
Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis
Objective. In recent years, pulmonary segmentectomy has emerged as an alternative to lobectomy for the treatment of patients with clinical stage I non-small cell lung cancer. Considering the conflicting results reported in the literature, the oncological effectiveness of segmentectomy remains contro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146149/ https://www.ncbi.nlm.nih.gov/pubmed/37109476 http://dx.doi.org/10.3390/life13040947 |
_version_ | 1785034511720906752 |
---|---|
author | Righi, Ilaria Maiorca, Sebastiano Diotti, Cristina Bonitta, Gianluca Mendogni, Paolo Tosi, Davide Nosotti, Mario Rosso, Lorenzo |
author_facet | Righi, Ilaria Maiorca, Sebastiano Diotti, Cristina Bonitta, Gianluca Mendogni, Paolo Tosi, Davide Nosotti, Mario Rosso, Lorenzo |
author_sort | Righi, Ilaria |
collection | PubMed |
description | Objective. In recent years, pulmonary segmentectomy has emerged as an alternative to lobectomy for the treatment of patients with clinical stage I non-small cell lung cancer. Considering the conflicting results reported in the literature, the oncological effectiveness of segmentectomy remains controversial. To provide new insight into oncological results, we reviewed the literature, including recent randomized trials. Methods. We performed a systematic review for surgical treatment of stage I NSCLC up to 2 cm using MEDLINE and the Cochrane Database from 1990 to December 2022. Primary outcomes for pooled analysis were overall and disease-free survival; secondary outcomes were postoperative complications and 30-day mortality. Results. Eleven studies were considered for the meta-analysis. The pooled analysis included 3074 and 2278 patients who received lobectomy and segmentectomy, respectively. The estimated pooled hazard ratio showed a similar hazard for segmentectomy compared to lobectomy in terms of overall and disease-free survival. The restricted mean survival time difference between the two procedures was statistically and clinically not significant for overall and disease-free survival. Nevertheless, the overall survival hazard ratio was time-dependent: segmentectomy was at a disadvantage starting from 40 months after surgery. Six papers reported 30-day mortality: there were no events on 1766 procedures. The overall relative risk showed that the postoperative complication rate was higher in segmentectomy compared to lobectomy, without statistical significance. Conclusions. Our results suggest that segmentectomy might be a useful alternative to lobectomy for stage I NSCLC up to 2 cm. However, this appears to be time-dependent; in fact, the risk ratio for overall mortality becomes unfavorable for segmentectomy starting at 40 months after surgery. This last observation, together with some still undefined questions (solid/non-solid ratio, depth of the lesion, modest functional savings, etc.), leave room for further investigations on the real oncological effectiveness of segmentectomy. |
format | Online Article Text |
id | pubmed-10146149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101461492023-04-29 Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis Righi, Ilaria Maiorca, Sebastiano Diotti, Cristina Bonitta, Gianluca Mendogni, Paolo Tosi, Davide Nosotti, Mario Rosso, Lorenzo Life (Basel) Systematic Review Objective. In recent years, pulmonary segmentectomy has emerged as an alternative to lobectomy for the treatment of patients with clinical stage I non-small cell lung cancer. Considering the conflicting results reported in the literature, the oncological effectiveness of segmentectomy remains controversial. To provide new insight into oncological results, we reviewed the literature, including recent randomized trials. Methods. We performed a systematic review for surgical treatment of stage I NSCLC up to 2 cm using MEDLINE and the Cochrane Database from 1990 to December 2022. Primary outcomes for pooled analysis were overall and disease-free survival; secondary outcomes were postoperative complications and 30-day mortality. Results. Eleven studies were considered for the meta-analysis. The pooled analysis included 3074 and 2278 patients who received lobectomy and segmentectomy, respectively. The estimated pooled hazard ratio showed a similar hazard for segmentectomy compared to lobectomy in terms of overall and disease-free survival. The restricted mean survival time difference between the two procedures was statistically and clinically not significant for overall and disease-free survival. Nevertheless, the overall survival hazard ratio was time-dependent: segmentectomy was at a disadvantage starting from 40 months after surgery. Six papers reported 30-day mortality: there were no events on 1766 procedures. The overall relative risk showed that the postoperative complication rate was higher in segmentectomy compared to lobectomy, without statistical significance. Conclusions. Our results suggest that segmentectomy might be a useful alternative to lobectomy for stage I NSCLC up to 2 cm. However, this appears to be time-dependent; in fact, the risk ratio for overall mortality becomes unfavorable for segmentectomy starting at 40 months after surgery. This last observation, together with some still undefined questions (solid/non-solid ratio, depth of the lesion, modest functional savings, etc.), leave room for further investigations on the real oncological effectiveness of segmentectomy. MDPI 2023-04-04 /pmc/articles/PMC10146149/ /pubmed/37109476 http://dx.doi.org/10.3390/life13040947 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Righi, Ilaria Maiorca, Sebastiano Diotti, Cristina Bonitta, Gianluca Mendogni, Paolo Tosi, Davide Nosotti, Mario Rosso, Lorenzo Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title | Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title_full | Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title_fullStr | Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title_full_unstemmed | Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title_short | Oncological Outcomes of Segmentectomy versus Lobectomy in Clinical Stage I Non-Small Cell Lung Cancer up to Two Centimeters: Systematic Review and Meta-Analysis |
title_sort | oncological outcomes of segmentectomy versus lobectomy in clinical stage i non-small cell lung cancer up to two centimeters: systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146149/ https://www.ncbi.nlm.nih.gov/pubmed/37109476 http://dx.doi.org/10.3390/life13040947 |
work_keys_str_mv | AT righiilaria oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT maiorcasebastiano oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT diotticristina oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT bonittagianluca oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT mendognipaolo oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT tosidavide oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT nosottimario oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis AT rossolorenzo oncologicaloutcomesofsegmentectomyversuslobectomyinclinicalstageinonsmallcelllungcanceruptotwocentimeterssystematicreviewandmetaanalysis |